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Abstract Since apoptosis of endothelial cells (ECs) plays an
important role in the pathogenesis of atherosclerosis, we inves-
tigated the e¡ect of cyclic stretch on EC apoptosis. Application
of moderate, physiologic levels of cyclic stretch (6^10% at 1 Hz)
inhibited EC apoptosis. This anti-apoptotic e¡ect was dependent
on the activation of phosphatidylinositol 3-kinase and associated
with the activation of Akt and the phosphorylation of Bad.
Interestingly, a higher potentially pathologic level of cyclic
stretch (20% at 1 Hz) stimulated EC apoptosis. The ability of
physiologic cyclic stretch to inhibit EC apoptosis may provide
a previously unrecognized mechanism by which hemodynamic
forces exert an anti-atherogenic e¡ect.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Emerging evidence suggests that apoptosis of endothelial
cells (ECs) plays a pivotal role in the development of athero-
sclerosis. Many of the classical pro-atherogenic factors, in-
cluding oxidized low density lipoprotein, in£ammatory cyto-
kines, and reactive oxygen species, are potent inducers of EC
apoptosis whereas known atheroprotective factors such as NO
and high density lipoprotein inhibit EC apoptosis [1^4]. Re-
cently, apoptotic ECs have been directly detected in human
coronary atherosclerotic plaques [5]. Interestingly, EC apopto-
sis and atherosclerotic lesions preferentially develop in regions
of disturbed blood £ow suggesting an important link between
local hemodynamic forces and the pathobiological processes
leading to EC death and atherosclerosis [5,6]. In support of
this hypothesis, laminar £uid shear stress has been shown to
be a potent inhibitor of EC apoptosis [7^9].
In addition to £uid shear stress, vascular ECs are continu-
ously subjected to cyclic stretch (or strain), which arises from
the periodic change in vessel diameter as a result of pulsatile
blood £ow. Recent studies indicate that cyclic stretch exerts
signi¢cant e¡ects on the vascular endothelium. The imposition
of cyclic mechanical stretch alters EC orientation and may
play a fundamental role in regulating vascular tone and blood
£uidity by stimulating the release of humoral factors from the
endothelium [10,11]. In the present study, we investigated
whether cyclic stretch also regulates EC death.
2. Materials and methods
2.1. Materials
Wortmannin and LY-294002 were from Alexis Biochemicals;
RNase A and proteinase K were from Boehringer Mannheim; re-
combinant human tumor necrosis factor-K (TNFK) was from Gen-
zyme; rabbit polyclonal Akt and sheep polyclonal phospho-Akt (Ser-
473) were from Upstate Biotechnology; phospho-Bad (Ser-136) anti-
body was from New England Biolabs; goat polyclonal L-actin anti-
body was from Santa Cruz Biotechnology; all other reagents were
from Sigma.
2.2. Cell culture
Bovine aortic ECs were purchased from VEC Technologies and
grown in Dulbecco’s modi¢ed Eagle’s medium supplemented with
10% serum, 5 mM TES, and 5 mM HEPES. Human aortic ECs
were purchased from Clonetics Corporation and grown in M199 me-
dium containing 20% serum, 50 Wg/ml endothelial cell growth supple-
ment, and 50 Wg/ml heparin. Culture media were supplemented with
penicillin (100 U/ml) and streptomycin (100 U/ml) and ECs propa-
gated in 5% CO2 at 37‡C.
2.3. Application of cyclic strain
ECs were plated onto 6-well Bio£ex plates coated with type I col-
lagen (Flexercell Corporation). The thickness of the silicon elastomer
on the bottom of the plate varies along the diameter of the plate such
that a near homogeneous strain pro¢le is obtained throughout the
membrane. Cells were subjected to mechanical deformation of 6^
20% at 1 Hz using the Flexercell Strain Unit (FX 3000, Flexercell
Corporation), as previously described [10].
2.4. Cell apoptosis and viability
Apoptosis was monitored by measuring DNA fragmentation and
the activation of caspase-3 [12]. DNA fragmentation was examined by
agarose gel electrophoresis while caspase-3 activity was determined
using a colorimetric assay which monitors the cleavage of the p-nitro-
anilide-conjugated caspase-3 substrate DEVD (Clontech). ECs
(1U106 cells) were trypsinized, washed in ice-cold phosphate-bu¡ered
saline (PBS), and suspended in lysis bu¡er (50 mM HEPES pH 7.5,
10% sucrose, 0.1% Triton X-100) on ice. Following centrifugation at
14 000Ug for 5 min at 4‡C, supernatants were incubated with 50 WM
of DEVD and absorbance measured at 405 nm. Cell viability was
assessed by measuring the uptake of the membrane-impermeable stain
trypan blue, as we have previously described [12].
2.5. Western blotting
Proteins were resolved by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) and blots electrophoretically trans-
ferred to nitrocellulose membranes and blocked in PBS and non-fat
milk (5%). Blots were incubated with antibodies directed against phos-
phorylated Akt (1:1000 dilution), Akt (1:1000 dilution), phospho-Bad
(1:500 dilution), or the housekeeping protein L-actin (1:100 dilution).
Membranes were then washed in PBS and incubated for 1 h with
horseradish peroxidase-conjugated goat anti-rabbit, rabbit anti-goat,
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or rabbit anti-sheep antibody. After further washing with PBS, blots
were incubated in commercial chemoluminescence reagents (Amer-
sham).
2.6. Mitochondrial cytochrome c release
EC lysates were fractionated, proteins (50 Wg) resolved by SDS^
PAGE, and cytochrome c analyzed by Western blotting, as we have
previously described [12], using a monoclonal antibody (5 Wg/ml)
(RpD Systems) that speci¢cally recognizes the denatured form of
cytochrome c.
2.7. Statistics
Results are expressed as the meansQS.E.M. Statistical analysis was
performed with a Student’s two-tailed t-test or ANOVA when more
than two treatments were compared. P values less than 0.05 were
considered to be statistically signi¢cant.
3. Results
Treatment of bovine aortic ECs with TNFK (40 ng/ml) for
48 h resulted in a marked decrease in the number of viable
cells (Fig. 1A). This cytotoxic e¡ect of TNFK was associated
with an increase in EC apoptosis, as re£ected by a pro-
nounced DNA ladder (Fig. 1B) and a signi¢cant elevation
in caspase-3 activity (Fig. 1C). However, the application of
cyclic stretch (6% at 1 Hz) reversed the apoptotic e¡ect of
TNFK on bovine aortic ECs. Cyclic stretch increased the
number of viable cells following cytokine treatment and
blocked cytokine-mediated DNA laddering and caspase-3 ac-
tivation (Fig. 1A^C). In addition, Western blot analysis re-
vealed that cytochrome c was found predominantly in the
membrane fraction in control ECs (Fig. 1D). As previously
reported [4], minor amounts of cytochrome c were also de-
tected in the cytosolic fraction of control ECs (Fig. 1D). This
likely represents leakage of cytochrome c from the mitochon-
dria during the fractionation procedure. However, following
TNFK treatment, substantial amounts of cytochrome c were
detected in the cytosolic fraction (Fig. 1D). This TNFK-medi-
ated translocation of cytochrome c from the membrane to the
cytosolic fraction was blocked by 6% cyclic stretch (Fig. 1D).
Exposure of bovine aortic EC to cyclic mechanical stretch also
inhibited DNA fragmentation following serum deprivation
(Fig. 2A). Similarly, application of cyclic stretch (6%) blocked
DNA laddering secondary to serum depletion in human aortic
ECs (Fig. 2B).
Interestingly, the cytoprotective action of cyclic strain was
dependent on the degree of strain. While 6 and 10% strain
protected bovine aortic ECs against TNFK-mediated cytotox-
icity, the application of 20% stretch failed to protect ECs (Fig.
3A). In fact, 20% cyclic stretch induced DNA laddering in
control ECs and potentiated TNFK-mediated DNA laddering
(Fig. 3B).
We next examined the molecular mechanism by which cy-
clic strain inhibits EC apoptosis. Since cyclic stretch stimulates
the synthesis of NO [10], a potent inhibitor of EC apoptosis
[3], we examined whether NO was a mediator of the anti-
apoptotic e¡ect of cyclic stretch. However, inhibition of NO
synthase with methyl-L-arginine (1 mM) failed to reverse the
inhibitory e¡ect of cyclic stretch (6%) on DNA laddering (Fig.
4A). In contrast, the phosphatidylinositol 3-kinase (PI3K) in-
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Fig. 1. Cyclic stretch (6%) inhibits TNFK (40 ng/ml for 48 h)-mediated apoptosis in bovine aortic ECs. A: E¡ect of cyclic stretch on cell viabil-
ity. Results are meansQS.E.M. of four separate experiments. B: E¡ect of cyclic stretch on DNA laddering. Data are representative of four sep-
arate experiments. C: E¡ect of cyclic stretch on caspase-3 activity. Results are meansQS.E.M. of three separate experiments. D: E¡ect of cyclic
stretch on the release of mitochondrial cytochrome c. Data are representative of three separate experiments. *Statistically signi¢cant e¡ect of
TNFK. þStatistically signi¢cant e¡ect of cyclic stretch.
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hibitors, wortmannin (100 nM) and LY-294002 (10 WM), re-
versed the anti-apoptotic e¡ect of cyclic stretch (6%) (Fig.
4B,C). These PI3K inhibitors had no e¡ect on TNFK-stimu-
lated apoptosis (Fig. 4B,C). Application of cyclic strain (6%)
to ECs also induced the activation of protein kinase, Akt,
which is a downstream target of PI3K [13]. Akt activity was
measured by Western blotting with a phosphospeci¢c Akt
antibody, which has been shown to correlate with enzyme
activity [14]. Exposure of vascular ECs to cyclic strain (6%)
stimulated the phosphorylation of Akt (Fig. 5A) and this was
not a¡ected by TNFK (data not shown). Since Akt has been
reported to phosphorylate and inactivate the pro-apoptotic
Bcl2 family member, Bad, we investigated the e¡ect of cyclic
stretch on Bad phosphorylation [15]. Exposure of ECs to cy-
clic strain (6%) induced the phosphorylation of Bad, as de-
tected by Western blotting with a phosphospeci¢c antibody
against the Akt phosphorylation site (Ser-136), and this was
blocked by the PI3K inhibitors wortmannin (100 nM) and
LY-294002 (10 WM) (Fig. 5B).
4. Discussion
In the present study, we are the ¢rst to demonstrate that
physiologic levels of cyclic stretch (6^10%) inhibit apoptosis in
arterial ECs. The anti-apoptotic e¡ect of these moderate levels
of cyclic stretch is dependent on the activation of PI3K and is
associated with the activation of Akt and the phosphorylation
of Bad. In contrast, a high level of cyclic stretch (20%) ac-
tually induces programmed cell death. These ¢ndings establish
cyclic stretch as a novel regulator of EC death.
Treatment of vascular ECs with TNFK stimulates apopto-
sis, as demonstrated by a decrease in cell viability, DNA lad-
dering, and caspase-3 activation. However, the simultaneous
application of cyclic stretch (6 and 10%) to vascular ECs ex-
erts a signi¢cant inhibitory e¡ect on cytokine-mediated apo-
ptosis. Similarly, cyclic stretch (6%) blocks apoptosis induced
by serum deprivation in both bovine and human aortic ECs,
suggesting that physiologic cyclic stretch functions as a gen-
eral inhibitor of vascular EC apoptosis. The levels of cyclic
stretch required to inhibit apoptosis are comparable to those
reported in large peripheral vessels under normotensive con-
ditions and thus represent physiologically relevant levels [15].
The mechanism by which cyclic stretch inhibits apoptosis in
ECs involves the activation of PI3K. We found that cyclic
stretch stimulates the phosphorylation and activation of
Akt, which is a downstream target of PI3K. Moreover, two
structurally dissimilar pharmacological inhibitors of PI3K,
wortmannin and LY-294002, are able to reverse the anti-
apoptotic e¡ect. Akt is a known inhibitor of apoptosis that
blocks programmed cell death by phosphorylating speci¢c
downstream targets. Akt stimulates the phosphorylation and
activation of endothelial NO synthase [16,17], and NO pro-
motes EC survival by inhibiting caspases via nitrosylation
[13]. However, NO does not mediate the anti-apoptotic e¡ect
of cyclic stretch since the NO synthase inhibitor, methyl-L-
arginine, fails to reverse the apoptosis-suppressive action of
cyclic stretch. Recently, Akt has been shown to stimulate the
phosphorylation and inactivation of the pro-apoptotic protein
Bad [13]. In its unphosphorylated form, Bad induces apopto-
sis by heterodimerization with other Bcl-2 family members,
leading to the release of cytochrome c from the mitochondria.
We found that cyclic stretch stimulates the phosphorylation of
Bad at Ser-136, in a PI3K-dependent manner. The phosphor-
ylation of Bad results in its association with cytoplasmic 14-3-
3 adapter proteins, thereby sequestering Bad from its targets
at the mitochondria [13]. The phosphorylation of Bad by cy-
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Fig. 2. Cyclic stretch (6%) inhibits apoptosis in bovine (A) and hu-
man (B) aortic ECs following 48 h of serum deprivation. Data are
representative of three separate experiments.
c
o
n
tr
o
l
s
tr
e
tc
h
 (
2
0
%
)
T
N
F
T
N
F
+
 s
tr
e
tc
h
 (
2
0
%
)A. B.
0
20
40
60
80
100
+
stretch
(6%)
+
stretch
(10%)
+
stretch
(20%)
+
α α
TNFα TNFα TNFα TNFα
∗
∗
V
ia
b
le
 C
e
ll
s
(%
 o
f 
c
o
n
tr
o
l)
Fig. 3. Anti-apoptotic e¡ect of cyclic stretch is dependent on the degree of cyclic stretch. A: E¡ect of cyclic stretch (6, 10, or 20%) on TNFK
(40 ng/ml for 48 h)-mediated cytotoxicity. Results are meansQS.E.M. of four separate experiments. *Statistically signi¢cant e¡ect of TNFK.
þStatistically signi¢cant e¡ect of cyclic stretch. B: E¡ect of cyclic stretch (20%) on TNFK (40 ng/ml for 48 h)-mediated DNA laddering. Data
are representative of three separate experiments.
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clic stretch likely contributes to its ability to block mitochon-
drial cytochrome c release. In addition to directly phosphor-
ylating Akt and Bad, cyclic stretch may further promote the
phosphorylation of these proteins by inhibiting the activity of
the serine/threonine-speci¢c phosphatase, PP2A [18]. Interest-
ingly, a recent study found that 10% cyclic stretch activates
Akt in vascular smooth muscle cells, suggesting that physio-
logic levels of stretch may also inhibit smooth muscle cell
apoptosis [19].
The capacity of cyclic stretch to inhibit vascular EC apo-
ptosis may play an important vasculoprotective and anti-athe-
rogenic role in the circulation. Apoptosis of ECs participates
in plaque development by promoting the in¢ltration of in£am-
matory cells and lipids into the intima of the vessel wall as
well as the proliferation and migration of underlying vascular
SMCs. Moreover, the recent ¢nding that a signi¢cant percent-
age of luminal ECs undergoes apoptosis in human atheroscle-
rotic plaques [5] suggests that this process may contribute to
plaque erosion and rupture. In addition, apoptotic ECs exhib-
it marked procoagulant activity and may enhance plaque
thrombogenicity following plaque rupture [20]. Thus, the ca-
pacity of physiologic cyclic stretch to block EC apoptosis may
play a critical role in limiting plaque progression, erosion, and
thrombosis.
Interestingly, the e¡ect of cyclic stretch on vascular cell
apoptosis is dependent on the magnitude of stretch. Although
physiologic levels of cyclic stretch (6^10%) inhibit EC death, a
higher level of cyclic stretch (20%) stimulates EC apoptosis.
This latter ¢nding complements recent studies in vascular
smooth muscle cells where elevated levels of cyclic stretch
(15 and 25%) have also been shown to induce apoptosis
[21,22]. Under these high levels of repetitive mechanical strain,
apoptosis appears to result from oxidative DNA damage and
the subsequent activation of the tumor suppressor p53 [23].
High levels of cyclic stretch are encountered in certain patho-
logical conditions, such as hypertension and following the
introduction of a venous graft into an artery [24^26]. In this
respect, increased rates of vascular cell apoptosis and death
have been reported in spontaneously hypertensive animals and
in experimental vein grafts [21,26,27]. Thus, the ability of high
levels of cyclic stretch to stimulate vascular cell apoptosis may
contribute to the pathological remodeling response observed
in hypertensive vessels or in vein grafts.
In conclusion, the present study identi¢ed cyclic stretch as a
critical regulator of EC survival. While physiologic levels of
cyclic stretch protect ECs against apoptosis via the activation
of the PI3K signaling pathway, higher, potentially patholog-
ical levels of mechanical stretch stimulate apoptosis. The abil-
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Fig. 4. Role of NO and PI3K in the anti-apoptotic e¡ect of cyclic
stretch (6%). A: E¡ect of methyl-L-arginine (L-NMA; 1 mM) on
TNFK (40 ng/ml for 48 h)-mediated DNA laddering in the presence
and absence of cyclic stretch. Data are representative of three sepa-
rate experiments. B: E¡ect of the PI3K inhibitors, wortmannin (W;
100 nM) or LY-294002 (LY; 10 WM), on TNFK (40 ng/ml for 48
h)-mediated cytotoxicity in the presence and absence of cyclic
stretch. Results are meansQS.E.M. of three separate experiments.
*Statistically signi¢cant e¡ect of TNFK. þStatistically signi¢cant ef-
fect of stretch. C: E¡ect of the PI3K inhibitors, wortmannin (W;
100 nM) or LY-294002 (LY; 10 WM), on TNFK (40 ng/ml for 48
h)-mediated DNA laddering. Data are representative of three sepa-
rate experiments.
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Fig. 5. Cyclic stretch stimulates the phosphorylation of Akt (Akt-P)
and Bad (Bad-P) in bovine aortic ECs. A: E¡ect of cyclic stretch
(6% for 30 min) on Akt-P. B: E¡ect of cyclic stretch (6% for 30
min) on Bad-P in the presence and absence of wortmannin (W; 100
nM) and LY-294002 (LY; 10 WM).
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ity of physiologic cyclic stretch to inhibit EC apoptosis may
represent a previously unrecognized mechanism by which he-
modynamic forces exert a vasoprotective and anti-atherogenic
e¡ect in the circulation.
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